Lexicon Pharmaceuticals, Inc. (LXRX)
$
1.37
-0.02 (-1.46%)
Key metrics
Financial statements
Free cash flow per share
-0.2826
Market cap
516 Million
Price to sales ratio
8.8312
Debt to equity
0.4747
Current ratio
4.1648
Income quality
0.8448
Average inventory
184.5 Thousand
ROE
-0.8363
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Lexicon Pharmaceuticals, Inc. is dedicated to the discovery, development, and commercialization of pharmaceutical products, having achieved a revenue of $31,081,000.00 indicating its niche market focus. The cost of revenue for the company is $616,000.00 showcasing its production and operational expenses. The company’s stock is identified with the symbol 'LXRX' in the market, and its gross profit ratio stands at 0.98 reflecting the efficiency of the company's production and sales operations. Furthermore, the operating income ratio is -6.34 indicating the company's operational profitability margin. The company is engaged in the development of orally-delivered small molecule drug candidates, including Sotagliflozin, which has successfully completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes, as well as LX9211, currently in Phase II clinical development for neuropathic pain management. Lexicon also maintains strategic collaborations and license agreements with Bristol-Myers Squibb Company and Genentech, Inc., enhancing its market presence. Founded in 1995, the company is headquartered in The Woodlands, Texas. In the investment landscape, the stock is affordable at $1.19 making it suitable for budget-conscious investors. Additionally, the stock exhibits a high average trading volume of 2,386,344.00 indicating strong liquidity. With a market capitalization of $497,856,438.00 the company is classified as a small-cap player within the biopharmaceutical sector. Lexicon Pharmaceuticals, Inc. is recognized as a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth within its field. Through its robust pipeline and strategic partnerships, Lexicon continues to strive toward enhancing healthcare outcomes while providing investors with potential opportunities for growth in a rapidly evolving market.
Is Lexicon Pharmaceuticals, Inc. (LXRX) a good investment?
Investing in Lexicon Pharmaceuticals, Inc. (LXRX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Lexicon Pharmaceuticals, Inc. (LXRX)'s stock forecast?
Analysts predict Lexicon Pharmaceuticals, Inc. stock to fluctuate between $0.28 (low) and $2.08 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Lexicon Pharmaceuticals, Inc.'s market capitalization?
As of 2025-10-28, Lexicon Pharmaceuticals, Inc.'s market cap is $497,856,438, based on 363,398,860 outstanding shares.
How does Lexicon Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Lexicon Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Lexicon Pharmaceuticals, Inc. (LXRX) stock?
To buy Lexicon Pharmaceuticals, Inc. (LXRX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for LXRX. Place an order (Market, Limit, etc.).
What is the best time to invest in Lexicon Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Lexicon Pharmaceuticals, Inc. stock ever split?
Lexicon Pharmaceuticals, Inc.'s last stock split was 1:7 on 2015-05-21.
How did Lexicon Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $31,081,000 | EPS: -$0.63 | Growth: -21.25%.
Where can I find Lexicon Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.lexpharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Lexicon Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Lexicon Pharmaceuticals, Inc. stock?
All-time high: $6.33 (2021-10-15) | All-time low: $0.28 (2025-03-03).
What are the key trends affecting Lexicon Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter
globenewswire.com
Presentations collectively highlight pilavapadin's potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP)
globenewswire.com
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter
seekingalpha.com
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Citi's Biopharma Back to School Conference September 3, 2025 1:45 PM EDT Company Participants Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst Okay. Welcome back, everyone, for those listening in the room and on the webcast.
globenewswire.com
THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite treatment with available over-the-counter and prescription pain relievers will be presented at PAINWeek 2025. The conference is being held September 2-4, 2025, at The Cosmopolitan in Las Vegas, Nevada.
globenewswire.com
THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of clinical data was presented Sunday, August 31, during an oral presentation at the European Society of Cardiology (ESC) 2025 Congress in Madrid, Spain.
globenewswire.com
THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School Conference on Wednesday, September 3 at 1:45 p.m. ET and at the H.C.
seekingalpha.com
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Craig B. Granowitz - Senior VP & Chief Medical Officer Lisa M.
zacks.com
Lexicon Pharmaceuticals (LXRX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to a loss of $0.17 per share a year ago.
globenewswire.com
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to submit IND Enrollment completion for SONATA Phase 3 study in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) on target for 2026 Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2025, and provided an update on key corporate milestones and accomplishments. “We continue to make great strides against the strategy we set forth as an R&D focused company,” said Mike Exton, Ph.D.
See all news
